MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) was the target of a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 52,208 shares, a growth of 171.7% from the April 15th total of 19,213 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 128,113 shares, the days-to-cover ratio is presently 0.4 days.

MDxHealth Price Performance

Shares of NASDAQ:MDXH opened at $0.98 on Friday. The company has a market capitalization of $48.74 million, a PE ratio of -1.47 and a beta of 1.60. The business has a fifty day moving average price of $2.47 and a two-hundred day moving average price of $3.25. MDxHealth has a 1 year low of $0.94 and a 1 year high of $5.33.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $23.90 million during the quarter, compared to the consensus estimate of $30.89 million. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. Sell-side analysts anticipate that MDxHealth will post -0.41 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MDXH. GSA Capital Partners LLP bought a new position in shares of MDxHealth during the 3rd quarter worth $48,000. Jefferies Financial Group Inc. bought a new position in shares of MDxHealth during the 3rd quarter worth $53,000. Russell Investments Group Ltd. bought a new position in shares of MDxHealth during the 3rd quarter worth $461,000. Kennedy Capital Management LLC bought a new position in shares of MDxHealth during the 3rd quarter worth $1,826,000. Finally, FreeGulliver LLC grew its stake in shares of MDxHealth by 104.7% during the 3rd quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock worth $1,176,000 after acquiring an additional 129,348 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on MDXH shares. William Blair lowered MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday. TD Cowen reissued a “buy” rating and issued a $1.50 price target (down from $7.00) on shares of MDxHealth in a research report on Thursday. Lake Street Capital lowered their price target on MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. Finally, BTIG Research lowered their price target on MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.63.

MDxHealth News Roundup

Here are the key news stories impacting MDxHealth this week:

• Positive Sentiment: Lake Street Capital cut its price target to $5.00 from $9.00, but reiterated a buy rating, suggesting meaningful upside from the current share price despite the reduced target. Lake Street Capital price target cut
• Positive Sentiment: BTIG Research also lowered its target to $4.00 from $7.00 while keeping a buy rating, indicating analysts still see recovery potential even after the earnings reset. BTIG Research price target cut
• Neutral Sentiment: MDxHealth reported first-quarter 2026 results, including revenue of $23.9 million and adjusted EPS of -$0.19, which investors are parsing for signs of operating improvement. Q1 2026 earnings report
• Negative Sentiment: The quarter missed Wall Street expectations on both profit and revenue, with EPS below estimates and sales well under consensus, reinforcing concerns about execution and growth momentum. Q1 2026 earnings miss
• Negative Sentiment: Management’s FY2026 revenue guidance of $110 million to $115 million came in below the market’s expectation of about $122.6 million, adding pressure to the stock after the earnings release. FY2026 guidance
• Negative Sentiment: William Blair downgraded MDxHealth from outperform to market perform, another sign that sentiment has cooled after the weak quarterly update. William Blair downgrade

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.